The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines for patients, healthcare systems, and society. As a community, ARM builds the future of medicine by convening the sector, facilitating influential exchanges on policies and practices, and advancing the narrative with data and analysis. We actively engage key stakeholders to enable the development of advanced therapies and to modernize healthcare systems so that patients benefit from durable, potentially curative treatments.
As the global voice of the sector, we represent more than 475 members across 25 countries, including emerging and established biotechnology companies, academic and medical research institutions, and patient organizations.
As the voice of the sector, ARM takes the lead on educating stakeholders on policy issues affecting the development of and patient access to regenerative medicines. For a full list of ARM’s presentations and publications, click here.
The regenerative medicine and advanced therapies sector raised a record $19.9B in funding in 2020, fueling the broader biotech sector and driving a rapidly advancing pipeline of potentially transformative therapies. Regulatory decisions are expected on a record eight new regenerative medicine products – and on a total of ten products across at least four geographies. It was a significant year of growth for ARM as well. The global voice of the sector grew by 80 members, reaching a total global membership of more than 380 organizations.
Produced by the Marwood Institute and funded by ARM, this report uses a “Transformative Therapy Value Model,” and demonstrates that durable cell or gene therapies for multiple myeloma, sickle cell disease, and hemophilia A could provide cumulative cost-savings of $33B over the next ten years.
How do we navigate the balance between transformative effect and cost in relation to other therapies? Are there benefits of single-administration therapies beyond what US managed care typically considers? What is needed to chart the way forward? Industry experts discuss the short and long-term impacts of COVID-19 on reimbursement of regenerative medicines in the webinar, featuring speakers with experience with some of the top commercial plans in the US.
“Innovative new therapies require equally innovative new payment models that align incentives for payers and the developers who are investing significant resources to help patients,” writes ARM CEO Janet Lambert in this editorial, featured in the Financial Times. The article provides an overview of the challenges of reimbursing innovative therapies, and how ARM is working to overcome them.
Comments
The Alliance for Regenerative Medicine (ARM) appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ (CMS) proposed payment updates to the fiscal year 2024 Hospital Inpatient Prospective Payment System (Proposed Rule).